Ceffect LC, 75 mg, intramammary ointment for lactating cows

国家: 爱尔兰

语言: 英文

来源: HPRA (Health Products Regulatory Authority)

有效成分:

Cefquinome sulphate

可用日期:

Emdoka bvba

ATC代码:

QJ01DE90

INN（国际名称）:

Cefquinome sulphate

剂量:

75 mg/syringe

药物剂型:

Intramammary ointment

处方类型:

POM: Prescription Only Medicine as defined in relevant national legislation

治疗组:

Cattle

治疗领域:

cefquinome

疗效迹象:

Antibacterial

授权状态:

Authorised

授权日期:

2014-05-09

产品特点

Health Products Regulatory Authority
23 July 2019
CRN008M06
Page 1 of 4
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Ceffect LC, 75 mg, intramammary ointment for lactating cows
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each prefilled intramammary syringe of 8 g contains:
ACTIVE SUBSTANCE:
Cefquinome 75 mg
(Equivalent to Cefquinome sulfate 88.92 mg)
EXCIPIENTS:
For the full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Intramammary ointment.
White to slightly yellowish ointment.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Cattle (lactating cows).
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the treatment of clinical mastitis in the lactating dairy cow
caused by the following cefquinome-susceptible
microorganisms: _Streptococcus uberis, Streptococcus dysgalactiae,
Staphylococcus aureus_ and_ Escherichia coli._
4.3 CONTRAINDICATIONS
Do not use in cases of hypersensitivity to cephalosporin antibiotics,
other ß-lactam antibiotics or to any of the excipients.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
None.
4.5 SPECIAL PRECAUTIONS FOR USE
_Special precautions for use in animals_
The product should be reserved for the treatment of clinical
conditions which have responded poorly or are expected to
respond poorly to other classes of antimicrobials or narrow spectrum
β-lactam antimicrobials.
Use of the product should be based on susceptibility testing of the
bacteria isolated from the animal. If it is not possible,
therapy should be based on local (regional, farm level)
epidemiological information about susceptibility of the target
bacteria.
Official, national and regional antimicrobial policies should be taken
into account when the product is used.
Use of the product deviating from the instructions given in the SPC
may increase the prevalence of bacteria resistant to
cefquinome and may decrease the effectiveness of treatment with
cephalosporins due to the potential for cross-resistance.
The feeding to calves of milk containing residues of cefquinome (i.e.
milk